Market Place
Sourcing Support
Brii Bio Presents Phase 2 Chronic Hep B Data At EASL 2024
07 Jun 2024 //
PR NEWSWIRE
Brii Biosciences Provides Corporate Update and Reports FY23 Financial Results
22 Mar 2024 //
PR NEWSWIRE
Brii punts HIV, depression, lung programs to potential partners
22 Mar 2024 //
FIERCE BIOTECH
VBI Vaccines shrinks `long-term burn` with $33M Brii Bio deal
14 Feb 2024 //
FIERCE PHARMA
Brii Biosciences Announces Agreement to Acquire VBI`s IP Rights in BRII-179
13 Feb 2024 //
PR NEWSWIRE
Brii Bio Presents Data Highlighting Progress Towards Achieving HBV Cure
13 Nov 2023 //
PR NEWSWIRE
VBI Vaccines Partner Brii Announces Results of Phase 2 Study Evaluating BRII-179
06 Sep 2023 //
BUSINESSWIRE
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
22 Aug 2023 //
PR NEWSWIRE
Brii pays VBI $15M for global rights to hepB program and more
06 Jul 2023 //
FIERCE BIOTECH
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
05 Jul 2023 //
PR NEWSWIRE
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio
05 Jul 2023 //
PR NEWSWIRE
Brii Bio Announces New Data from Partners for HBV Functional Cure at EASL
25 Jun 2023 //
PR NEWSWIRE
Brii Bio Announces Agreements with Qpex & Acquiring Global Rights for BRII-693
25 Jun 2023 //
PR NEWSWIRE
Brii Biosciences Announces First Subject Dosed in Phase 1 Trial of BRII-297
31 May 2023 //
PR NEWSWIRE
Brii Biosciences halts manufacture of COVID-19 antibody combo
25 Mar 2023 //
FIERCE PHARMA
Brii Provides Corporate Update and Reports Full-Year 2022 Financial Results
24 Mar 2023 //
PR NEWSWIRE
Brii Biosciences Provides Update on Strategic Clinical Development Progress
28 Dec 2022 //
PRNEWSWIRE
Brii Presents Data to Support Development of Novel HIV Therapeutic Candidates
19 Oct 2022 //
PRNEWSWIRE
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296
26 Sep 2022 //
PRNEWSWIRE
Brii Biosciences Appoints Taiyin Yang to Board of Directors
31 Aug 2022 //
PRNEWSWIRE
Brii Bio Appoints Eleanor de Groot as CTO; A. Skuban as CNS Disease Area Head
22 Aug 2022 //
PRNEWSWIRE
Brii Bio Announces Positive Data on Long-Acting COVID-19 Neutralizing Ab Therapy
26 Jul 2022 //
PRNEWSWIRE
Brii Bio Enters Strategic Partnership with China Resources PCG
18 Jul 2022 //
PRNEWSWIRE
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
13 Jul 2022 //
PRNEWSWIRE
Brii Bio to Launch Amubarvimab/Romlusevimab Comb. Therapy for COVID-19 in China
06 Jul 2022 //
PRNEWSWIRE
Brii Bio Exercises Option for Vir`s VIR-3434 Targeting Hepatitis B
04 Jul 2022 //
ASIAONE
Brii Biosciences to be Added to MSCI China Small Cap Index
24 May 2022 //
PRNEWSWIRE
Brii Bio Announces Positive Data on Long-Acting COVID-19 Neutralizing Ab Therapy
09 May 2022 //
PRNEWSWIRE
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
06 May 2022 //
PRNEWSWIRE
Brii Bio Presents New Data on BRII-835 in Chronic Hepatitis B at APASL 2022
31 Mar 2022 //
PRNEWSWIRE
Brii Bio, Sinopharm Partner for Long-Acting COVID-19 Neutralizing Ab Therapy
29 Mar 2022 //
PRNEWSWIRE
Brii Biosciences Reports Full Year 2021 Financial Results
22 Mar 2022 //
PRNEWSWIRE
Brii Bio Appoints Karen D. Neuendorff as CPO and Head of HR
27 Jan 2022 //
PRNEWSWIRE
VBI Vaccines, Brii Bio Begin Dosing in 2nd Phase 2 Study in Chronic Hepatitis B
05 Jan 2022 //
BUSINESSWIRE
Brii Bio’s tests show combo therapy retains activity against Omicron
13 Dec 2021 //
PHARMACEUTICAL-TECHNOLOGY
Brii Bio`s MAb Combination Retains Neutralizing Activity Against Omicron
11 Dec 2021 //
PRNEWSWIRE
Brii says its COVID-19 Ab cocktail retains activity against Omicron
11 Dec 2021 //
REUTERS
China approves Brii Biosciences antibody COVID treatment
10 Dec 2021 //
REUTERS
China approves Brii COVID treatment in adults, teenagers
08 Dec 2021 //
REUTERS
Novartis-partnered DARPin flames out in COVID-19 study
17 Nov 2021 //
FIERCEBIOTECH
Hansoh, J&J, Brii and more—Fierce Pharma Asia
22 Oct 2021 //
FIERCEPHARMA
Brii Bio seeks FDA EUA for BRII-196/BRII-198 in non-hospitalized Covid patients
11 Oct 2021 //
PHARMABIZ
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA
08 Oct 2021 //
ASIAONE
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198,SARS-CoV-2
03 Oct 2021 //
PRNEWSWIRE
Brii Bio Appoints Coy Stout as Senior Vice President
27 Sep 2021 //
PRNEWSWIRE
Brii Bio Adds US$100M to Advance its Monoclonal Antibody Combination Therapy
07 Sep 2021 //
PRNEWSWIRE
Brii Bio touts early win in NIH study for a combo already used in China
25 Aug 2021 //
ENDPTS
Brii`s COVID-19 antibody slashes hospitalizations and deaths
25 Aug 2021 //
FIERCEBIOTECH
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial
24 Aug 2021 //
PRNEWSWIRE
NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies
06 Aug 2021 //
PHARMACEUTICAL TECHNOLOGY
Brii Biosciences Announces the Completion of Enrollment in NIH ACTIV-2 Trial
05 Aug 2021 //
PRNEWSWIRE
Brii, now public, expects Q4 COVID-19 antibody cocktail readout
14 Jul 2021 //
FIERCEBIOTECH
Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO
13 Jul 2021 //
ENDPTS
Brii Biosciences present positive data from phase 1b / 2a study of BRII-179
26 Jun 2021 //
BUSINESSWIRE
Brii Bio and VBI Vaccines Present Positive Data from Phase 1b/2a on BRII-179
23 Jun 2021 //
BUSINESSWIRE
Brii Bio and VBI Vaccines present data from phase 1b / 2a study of BRII-179
22 Jun 2021 //
BUSINESSWIRE
Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601)
09 Jun 2021 //
BUSINESSWIRE
VBI Vaccines Announces Abstracts Accepted for Poster Presentations at EASL 2021
09 Jun 2021 //
PRESS RELEASE
Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198,
29 Apr 2021 //
BUSINESSWIRE
Brii Biosciences` COVID-19 antibody combo cleared for phase 3
29 Apr 2021 //
FIERCE BIOTECH
